Mesalazine Regulates DUSP1, DUSP4, and DUSP5 Expression in Colorectal Cancer: In Vitro and Bioinformatic Evidence
Open Access
- 25 December 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 29
Abstract
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, with its development closely linked to dysregulation of mitogen-activated protein kinase (MAPK) signaling pathways. Background: Dual-specificity phosphatases (DUSPs), as key regulators of MAPKs, play a crucial role in maintaining the balance between proliferation and apoptosis. Methods: In this study, we investigated the effect of mesalazine (MES) on the expression and activity of selected DUSP family members in normal colon epithelial cells (CCD-841CoN) and colorectal cancer cells (DLD-1). Results: Microarray analysis identified 24 transcripts with altered expression upon mesalazine treatment. The number of significantly regulated genes decreased with increasing fold-change (FC) thresholds, from 20 genes (FC > 1.1) to 13 (FC > 1.5) and 5 (FC > 2.0), all with p < 0.001. Among the DUSP genes, DUSP4 and DUSP5 showed the most pronounced and cell-type-dependent modulation. Mesalazine upregulated DUSP4 and DUSP5 expression in DLD-1 cells (p < 0.001), while reducing their expression in normal CCD-841CoN cells. ELISA confirmed a 1.56-fold increase in DUSP5 protein concentration in mesalazine-treated cancer cells compared with controls (p < 0.001). Conclusions: These findings suggest that mesalazine differentially modulates DUSP gene expression in normal and malignant colon epithelial cells, potentially contributing to its antiproliferative and pro-apoptotic effects through the regulation of MAPK signaling. These results provide new insights into the molecular mechanisms underlying the anticancer effects of mesalazine in colorectal cancer.Keywords
Funding Information
- the Medical University of Silesia, Katowice, Poland (BNW-1-040/K/4/I)
This publication has 26 references indexed in Scilit:
- Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapySignal Transduction and Targeted Therapy, 2024
- Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatmentsCancer and Metastasis Reviews, 2023
- BAF53A drives colorectal cancer development by regulating DUSP5-mediated ERK phosphorylationCell Death & Disease, 2022
- Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanismsBiomedicine & Pharmacotherapy, 2022
- CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual-specificity phosphatase 1Carcinogenesis, 2021
- Genetic and biological hallmarks of colorectal cancerGenes & Development, 2021
- DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesisScientific Reports, 2018
- Mesalamine Inhibits Epithelial β-Catenin Activation in Chronic Ulcerative ColitisGastroenterology, 2010
- The MAPK signalling pathways and colorectal cancerThe Lancet Oncology, 2005
- Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2003